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A B S T R A C T
Bone metastases often appear in advanced stages of lung cancer. They are the result of modulation of bone metabolism
by tumor cells that migrated into bone microenvironment and degraded bone organic matrix. Measurement of C-termi-
nal telopeptide of type I collagen (ICTP) in the serum of subjects with lung cancer with and without bone metastases and
healthy population is the way to explore bone resorption. In 343 subjects included in this research ICTP level was signifi-
cantly higher in the bone metastasis than other two groups. The existence of pathologic fracture significantly increased
ICTP level. ICTP showed sensitivity of 66.0% in bone metastases at 95.0% specificity in lung cancer stages IA and IB.
ICTP is a good diagnostic marker in detection of bone metastasis of lung cancer. Its level can distinguish lung cancer
with and without bone involvement and can be used as an addition to standard techniques used in diagnostics of bone
metastasis.
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Introduction
Lung cancer frequently develops bone metastases in
advanced stages of disease. At initial diagnosis 16% of
non-small cell lung cancer (NSCLC) and 38% of small cell
lung cancer (SCLC) patients present with bone meta-
stasis1. At the time of death, the majority of patients
have bone metastases2.
Lung cancer metastases to bone are predominantly
osteolytic. Osteolysis results from the increased number
and activity of osteoclasts in bone remodeling process.
Once caught in the bone marrow vasculature, tumor
cells adhere to endothelial cells, and extravasate to bone
microenvironment3. The attachment to bone matrix is
facilitated by bone sialoprotein (BSP), often overexpres-
sed in lung cancer cells4–7. It is assumed that tumor cells
bind to BSP through the integrin avb3 expressed on their
surface whilst glutamate-rich regions of BSP attach to
crystals of hydroxyapatite8.
In the bone microenvironment tumor cells secrete
parathyroid hormone-related peptide (PTHrP) which sha-
res 70% homology with parathyroid hormone (PTH) and
has similar biologic function binding to PTH/PTHrP
receptors9–12. PTHrP stimulates the production of recep-
tor activator of nuclear factor-kB ligand (RANKL) on the
surface of stromal cells and osteoblasts. RANKL then
binds to receptor activator of nuclear factor-kB (RANK)
on osteoclast progenitors. Activation of transcription fac-
tors AP1 and NF-kB in osteoclast progenitors leads to
their differentiation13.
Simultaneously, PTHrP binds to PTH/PTHrP recep-
tors in kidneys and stimulates the tubular resorption of
calcium what causes hypercalcaemia which is one of the
typical traits of bone metastasis14.
Degradation of bone matrix which is rich with growth
factors causes their release into the bone microenviron-
ment. The release of TGF-b subsequently induces the sig-
nal transduction of Smad proteins15–17. This process sti-
mulates the proliferation of tumor cells and their produc-
tion of PTHrP which closes the »vicious circle« of the
osteolytic bone metastasis.
In optimal pH from 4,7 to 6,8 cathepsin K from osteo-
clasts can cleave collagen fibers on several sites on triple
helix, but primarily on telopeptide region generating
fragments from 70 to 80 kDa18–20. Its concentration in os-
teoclasts is the highest relative to cathepsins S, L and
B21.
Osteoclasts strongly express matrix-metalloproteina-
se 9 (MMP-9) which is beside MMP-2 an enzyme that has
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an ability to cleave denaturated collagen type I between
residues 775 and 776 thus generating N and C-terminal
fragments in optimally neutral pH19,22–24. The positive
correlation between serum levels of MMP-9 and ICTP
has been proven by Ylisirniö et al.25.
Normally, the pH value in subosteoclastic resorption
zone ranges from 3.5 and 4.5, but it is hypothesized that
the buffer activity of dissolved salts from the bone (Ca2+
and PO43–) shifts the pH value towards the neutral18,20.
The C-terminal telopeptide of type I collagen (ICTP)
is found only in C-terminal part of the mature collagen
type I in which the crosslinks between fibrils have been
formed. Since the 90% of bone organic matrix is com-
posed of collagen type I that makes ICTP good potential
marker of bone resorption process.
Increased ICTP levels can be found in bone metasta-
ses of breast, prostate, lung cancer and other malig-
nancies26,27. ICTP levels can discriminate lung cancer
with and without bone metastasis26. Also, ICTP level re-
flects the extent of skeletal involvement and the associ-
ated bone pain26,27. It has been proven to be a good prog-
nostic marker in lung cancer elevated level implying
higher risk of death than those below cut-off value25.
The aim of this study is to investigate the level of
ICTP in lung cancer with proven bone metastases, lung
cancer in stage IA or IB prior to surgery and phenotypic
healthy individuals, and to test the differences in ICTP
level between studied groups.
The clinical application of ICTP depends on popula-
tion characteristics, patient medical history, sample size
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TABLE 1







Number 144 99 100
Gender
Male 101 74 31
Female 43 25 69
Age 64.0±10.2 62.8±9.9 46.6±12.4
Histological type of
lung cancer
Adenocarcinoma 60 27 –
Squamous cell carcinoma 38 46 –
Small cell lung cancer 12 2 –
Adenosquamous or other mixed types of
non-small cell lung cancer
10 3
Large cell carcinoma 3 7 –
Carcinoids 1 11
Other (other mixed types, non-differentiated) 20 3 –
Stage
IA – 16 –
IB 83
Pathologic fracture
Present 19 – –
Not present 125 – –
Months after initial diagnosis of lung cancer 0–84.0±13.0 – –
Number of affected
metastatic sites
1 104 – –
2 17 – –
3 12 – –
4 7 – –
5 and more 4 – –
Location of bone
metastasis
Rib 69 – –
Vertebra 64 – –
Pelvis 20 – –
Femur 18 – –
Scapula 14 – –
Humerus 10 – –
Calvarial bones 8 – –
Sternum 5 – –
Clavicle 4 – –
Other 15
included in research, sampling time in relation to other
diagnostic invasive procedures, and clinically defined
control groups that are expected to have a different dy-
namics of ICTP level than the healthy population.
Subject selection
Samples from 144 lung cancer patients with bone me-
tastasis were obtained at the time of the first evidence of
osteolytic lesions proven by scinthigraphy and x-ray scans,
before treatment of bone metastases by irradiation and
biphosphonates.
Second group is consisted of 99 lung cancer patients
who underwent surgical treatment (lobectomy or pneu-
monectomy). Samples were collected at the time of diag-
nosis prior to surgery, and patient selection has been
made according to the pathologic diagnosis made after
surgical treatment, so only the patients in stage IA or IB
were selected in order to be positive there was no disease
spreading outside the thoracic wall.
Third group is composed of 100 healthy individuals
who had no visible symptoms of any disease nor had
knowledge about any disease or disorder.
Marker assay
Blood samples were collected by standard venipun-
cture into sterile tubes containing clot activator. After
centrifugation sera were stored at –20°C until analysis.
ICTP measurement was done using commercially
available immunoassay Uniq ICTP EIA (Orion Diag-
nostica, Finland), according to the manufacturer’s in-
structions. ICTP concentration is given in mg/L.
Statistical analysis
Differences between groups were tested by Mann-
-Whitney U-test or Kruskal-Wallis ANOVA on Statistica
7.1 software package (Statsoft, USA). ROC curves were
calculated using Analyse-it 1.73 (Analyse-it Software,
UK).
P-value below 0.05 was considered significant.
Results
The characteristics of 343 subjects enrolled in the
study are presented in Table 1.
Highest median ICTP levels are seen in lung cancer
patients with bone metastasis (Table 2).
Comparison between groups revealed significant dif-
ferences between the bone metastasis population and
other two groups (Figure 1). Also, significant differences
have been found between the population of patients in
stage IA and IB and phenotypic healthy individuals, but
not to the extent as in comparison with bone metastasis
patients.
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TABLE 2
SERUM LEVEL OF ICTP IN THREE GROUPS OF STUDIED POPULATION
Patients with bone metastasis Patients in stage IA/IB Healthy individuals
Median ICTP (mg/L) 12.0 5.8 4.3












Fig. 1. Comparison of ICTP levels between groups. BM=patients

























Fig. 2. a) Comparison in ICTP level among various histological
types of lung cancer with bone metastasis; b) Differences in ICTP
level between patients without and with pathologic fracture.
NS=non-significant, AD=adenocarcinoma, SQC=squamous cell
carcinoma, LCC=large cell carcinoma, Other NSCLC= adeno-
squamous and other mixed types of non-small cell lung cancer,
C=carcinoid, SCLC=small cell lung cancer.
The comparison of ICTP levels according to the his-
tological type of lung cancer in bone metastasis group did
not reveal any significant correlation (Figure 2a). On the
contrary, Mann-Whitney U-test showed significant dif-
ferences in ICTP level between subjects with and with-
out pathologic fracture as a result of bone metastasis
(Figure 2b). Obtained median ICTP value in patients
without the fracture is 11.7 mg/L and with pathologic
fracture 20.1 mg/L.
Furthermore, ROC curve is constructed using two
datasets; truly positive=patients with proven bone me-
tastasis, and truly negative=lung cancer stage IA or IB
(Figure 3).
The cut-off value of 9.9 mg/L is selected from the ROC
curve which corresponds to 66.0% of sensitivity and
95.0% of specificity. That gives positive predictive value
of 95.0% and negative predictive value of 65.7%.
Discussion
The results obtained in this research show signifi-
cantly higher ICTP values in lung cancer with bone me-
tastasis than in lung cancer in stages IA and IB and
phenotypic healthy population. This confirms the mech-
anism of osteolyis in lung cancer bone metastasis result-
ing predominantly from the increased osteoclast matura-
tion and activation and subsequent bone organic matrix
degradation13,25. The median ICTP value in patients in
stage IA and IB is closer to the one measured in healthy
population suggesting the absence of increased bone re-
sorption in the early stages of lung cancer.
All three groups compared together showed signifi-
cant differences between lung cancer with bone meta-
stases and other two groups. Such differences have been
previously found in breast, lung and prostate cancer with
and without bone metastasis26,28–30. The ability of ICTP
to discriminate between lung cancer with and without
bone metastasis suggests its use as a potential marker of
bone collagen degradation in the advanced stages of lung
cancer where there is suspicion about bone involvement
based on symptoms and available imaging techniques.
The difference in ICTP levels between lung cancer of
stage IA and IB and phenotypic healthy population can
be explained by the destruction of extracellular matrix
surrounding primary lung tumor. Although not as high
as the ones obtained by the comparison with the bone
metastasis group these differences suggest a certain level
of degradation of collagen fibers in the epithelial tissue
and stroma built from the helical units of collagens I and
III31. These results have been previously described in
lung cancer25.
The histological type of lung cancer with bone metas-
tasis did not significantly influence ICTP levels as the
mechanism of osteoclast activation being common to all
predominantly osteolytic bone metastasis.
The existence of pathologic fracture influenced signif-
icantly the ICTP level being higher than in bone metas-
tasis without fracture. These results confirm that the in-
crease in serum level of ICTP is mainly a consequence of
tumor involvement of the bone organic matrix that is
more advanced in patients who have pathologic frac-
tures.
ROC curve revealed very good AUC and ratio of sensi-
tivity and specificity. The high sensitivity in bone metas-
tasis makes ICTP good diagnostic marker as an addi-
tional tool to standard diagnostic techniques. ICTP can
be primarily used in monitoring of lung cancer patients
with the suspicion, increased risk or already present
bone metastasis because its level reflects bone resorption
resulting from modulation of bone metabolism by tumor
cells.
Conclusion
This research showed that ICTP is good diagnostic
tool that can detect bone metastasis of lung cancer with
high sensitivity. Also, it can be used to distinguish lung
cancer with and without bone metastasis. These results
suggest its application as a complement to standard diag-
nostic techniques in diagnosis and monitoring of the ad-
vanced lung cancer with high risk of bone involvement or
already present bone metastasis.
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Fig. 3. ROC curve for discrimination of bone metastasis from
stage IA/IB lung cancer. AUC=0.891, 95% CI of AUC=0.851 to
0.931, p<0.0001; =ICTP.
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ICTP KOD KO[TANIH METASTAZA RAKA PLU]A
S A @ E T A K
Ko{tane metastaze ~esto su prisutne u uznapredovanim stadijima raka plu}a. One su rezultat modulacije ko{tanog
metabolizma od strane tumorskih stanica koje su migrirale u ko{tanu mikrookolinu i degradirale ko{tani organski
matriks. Mjerenje C-terminalnog telopeptida kolagena tipa I (ICTP) u serumu ispitanika sa i bez ko{tanih metastaza,
te zdravoj populaciji, na~in je na koji je mogu}e ispitati ko{tanu resorpciju. Kod 343 ispitanika obuhva}enih istra-
`ivanjem razina ICTP-a bila je zna~ajno vi{a kod ko{tanih metastaza, nego kod preostale dvije grupe. Postojanje pato-
lo{ke frakture zna~ajno je utjecalo na pove}anje razine ICTP-a. ICTP je pokazao senzitivnost od 66,0% kod ko{tanih
metastaza koja odgovara 95,0%-tnoj specifi~nosti kod raka plu}a stadija IA i IB. ICTP je dobar dijagnosti~ki biljeg za
detekciju ko{tanih metastaza raka plu}a. Njegovom razinom mogu}e je razlikovati rak plu}a sa i bez zahva}enosti
kostiju, te se mo`e koristiti kao dodatak standardnim tehnikama dijagnostike ko{tanih metastaza.
A. Franjevi} et al.: ICTP in Bone Metastases of Lung Cancer, Coll. Antropol. 35 (2011) 1: 43–47
47
